As it readies its civil penalty suit against tech company Nuix for trial, ASIC has flagged a possible dispute about the extent of penalty privilege pleaded by a handful of former and current directors named in the case.
Global law firm Jones Day has recruited two partners for its growing energy practice, including a former Ashurst partner.
A 16-year battle between the federal government and drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix has gone to the High Court.
Jones Day has added a corporate transactions counsel who spent 12 years working in New York, most recently at Latham & Watkins LLP, to join its Sydney team.
Companies could be on the hook for higher penalties for foreign bribery and other white collar offences after a High Court majority on Wednesday found a $1.35 million bribery penalty imposed on engineering firm Jacobs Group was inadequate.
A judge has upheld findings from IP Australia that South Korean biotech ToolGen’s genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.
Jones Day has recruited White & Case lawyer Kathryn Sutherland-Smith for the firm’s business restructuring & reorganization practice in Sydney.
Johnson Winter Slattery has nabbed a Jones Day partner to work coast to coast at its Brisbane and Perth offices, bolstering the ranks of its disputes and insolvency team.
Drug maker Sanofi-Aventis is not liable for the federal government’s losses for excess subsidies paid for the blood-thinner Plavix after an allegedly unjustified court injunction prevented the release of a generic version of the blockbuster drug, an appeals court has found.
Texas oil giant Tri-Star has lost its bid for a referral in a dispute with natural gas exporter Australia Pacific LNG over several coal seam gas fields in Queensland and $7.6 billion in share acquisitions.